A trio of investigational drugs led to a hepatitis C cure rate of 89% to 94% after 12 weeks in a Phase II study. Researchers said the drug combo -- once daily daclatasvir, twice daily asunaprevir and a twice-daily non-nucleoside NS5B polymerase inhibitor -- generally was well tolerated and may offer an HCV treatment that is free of interferon and ribavirin, which are part of standard therapy. The study results were presented at a conference and are preliminary.

Related Summaries